Scholar Rock Holding Corporation - Common Stock (NQ:SRRK)

46.09 UNCHANGED

Delayed Quote Updated: 4:00 PM EST, Nov 4, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Scholar Rock Holding Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Why Scholar Rock Stock Bounced Higher on Monday ↗

September 15, 2025

One pundit believes the share price could rise in excess of 50%.

Via The Motley Fool

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 12, 2025

From Scholar Rock

Via Business Wire

How Do Investors Really Feel About Scholar Rock Holding? ↗

September 08, 2025

Via Benzinga

Here's How Much $1000 Invested In Scholar Rock Holding 5 Years Ago Would Be Worth Today ↗

September 01, 2025

Via Benzinga

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 15, 2025

From Scholar Rock

Via Business Wire

Earnings Scheduled For August 6, 2025 ↗

August 06, 2025

Via Benzinga

Pivotal SAPPHIRE Trial Data Published in The Lancet Neurology: Apitegromab Demonstrated Significant Motor Function Gains for Children and Adults with SMA on SMN-Targeted Treatment

August 14, 2025

From Scholar Rock

Via Business Wire

Here's How Much You Would Have Made Owning Scholar Rock Holding Stock In The Last 5 Years ↗

August 07, 2025

Via Benzinga

Why Scholar Rock Stock Wilted on Wednesday ↗

August 06, 2025

The market was hoping the company could better contain its losses.

Via The Motley Fool

Scholar Rock (SRRK) Q2 Loss Widens 63% ↗

August 06, 2025

Via The Motley Fool

Scholar Rock Holding Corp (NASDAQ:SRRK) Reports Q2 2025 Wider Loss but Market Shows Optimism Ahead of Key FDA Decision ↗

August 06, 2025

Scholar Rock reports Q2 2025 loss of $0.98 per share but gains investor optimism ahead of FDA decision for apitegromab in SMA. Cash runway extends to 2027.

Via Chartmill

Scholar Rock Reports Second Quarter 2025 Financial Results and Highlights Business Progress

August 06, 2025

From Scholar Rock

Via Business Wire

Director Sells 11,136 Shares of SRRK, a Stock Up 330% in Past Year ↗

July 23, 2025

Via The Motley Fool

Topics Regulatory Compliance

Scholar Rock to Host Conference Call to Discuss Second Quarter 2025 Financial Results and Provide Business Update on August 6, 2025

July 21, 2025

From Scholar Rock

Via Business Wire

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 18, 2025

From Scholar Rock

Via Business Wire

Scholar Rock to Present Comprehensive Update at 2025 Annual Cure SMA Research and Clinical Care Meeting, Including Positive Results from Pivotal Phase 3 SAPPHIRE Trial

June 23, 2025

From Scholar Rock

Via Business Wire

Scholar Rock Stock Soars After Investigational Drug Helps Preserve Lean Mass: Retail Flags Lack Of Incremental Weight Loss ↗

June 18, 2025

Apitegromab therapy with Tirzepatide preserved an additional 4.2 pounds of lean mass compared to Tirzepatide alone in the study, the company said.

Via Stocktwits

Topics Death

Why Scholar Rock Shares Are Soaring Today ↗

June 18, 2025

Via The Motley Fool

Topics Stocks

Scholar Rock's Atrophy Drug When Combined With Eli Lilly's Zepbound Shows Around 55% Better Muscle Preservation In Weight Loss Study ↗

June 18, 2025

Scholar Rock's apitegromab helped preserve muscle mass during tirzepatide-induced weight loss, improving overall body composition in Phase 2 trial.

Via Benzinga

Which stocks are gapping on Wednesday? ↗

June 18, 2025

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Wednesday.

Via Chartmill

Wondering what's happening in today's pre-market session? ↗

June 18, 2025

The US market session of Wednesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.

Via Chartmill

Scholar Rock Reports Positive Phase 2 EMBRAZE Trial Results Demonstrating Statistically Significant Preservation of Lean Mass with Apitegromab During Tirzepatide-Induced Weight Loss

June 18, 2025

From Scholar Rock

Via Business Wire

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 13, 2025

From Scholar Rock

Via Business Wire

Jefferies Names Akero Therapeutics, Scholar Rock As Biotech Companies With Takeover Potential, But Retail Isn’t Pleased ↗

June 13, 2025

Jefferies thinks big pharma companies are "still on the hunt" for deals.

Via Stocktwits

Greif Posts Upbeat Earnings, Joins Planet Labs PBC, IperionX, Owens & Minor And Other Big Stocks Moving Higher On Thursday ↗

June 05, 2025

Via Benzinga

Scholar Rock to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

June 05, 2025

From Scholar Rock

Via Business Wire

Scholar Rock Appoints Rebecca McLeod Chief Brand Officer and U.S. General Manager

June 02, 2025

From Scholar Rock

Via Business Wire

Scholar Rock to Present at the Jefferies Global Healthcare Conference

May 28, 2025

From Scholar Rock

Via Business Wire

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 16, 2025

From Scholar Rock

Via Business Wire

Scholar Rock Reports First Quarter 2025 Financial Results and Highlights Business Progress

May 14, 2025

From Scholar Rock

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.